检索范围:
排序: 展示方式:
View-invariant human action recognition via robust locally adaptive multi-view learning
Jia-geng FENG,Jun XIAO
《信息与电子工程前沿(英文)》 2015年 第16卷 第11期 页码 917-920 doi: 10.1631/FITEE.1500080
关键词: View-invariant Action recognition Multi-view learning L1-norm Local learning
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li
《医学前沿(英文)》 2019年 第13卷 第4期 页码 438-450 doi: 10.1007/s11684-018-0674-4
关键词: PD-1 PD-L1 immune checkpoint blockade antibody immunotherapy cervical cancer
《医学前沿(英文)》 页码 805-822 doi: 10.1007/s11684-023-1025-7
关键词: CTLA-4 PD-1 PD-L1 immune checkpoint blockade (ICB) metabolic reprogramming combined tumor therapeutic strategies
Activation of phagocytosis by immune checkpoint blockade
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 473-480 doi: 10.1007/s11684-018-0657-5
Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.
关键词: CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage
Influence and related mechanism of Retn gene expression on glucose uptake in 3T3-L1 cells
LI Yahui, DONG Shiyuan, YU Chao, JIANG Yu, LI Huaixing, SUN Shuhan
《医学前沿(英文)》 2007年 第1卷 第3期 页码 269-273 doi: 10.1007/s11684-007-0051-1
关键词: 3T3-L1 influence resistance receptor substrate-1 transport
王昊1,王志远1,王本冬1,金仲和1,John L. CRASSIDIS2
《信息与电子工程前沿(英文)》 2021年 第22卷 第2期 页码 141-286 doi: 10.1631/FITEE.1900358
关键词: 红外地球敏感器;微小卫星;姿态确定系统
Chao WU,Lu-ping XU,Hua ZHANG,Wen-bo ZHAO
《信息与电子工程前沿(英文)》 2015年 第16卷 第9期 页码 796-804 doi: 10.1631/FITEE.1500058
关键词: Threshold detection Discrete chirp-Fourier transform Block zero-padding High dynamic Weak L1 signal acquisition
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
of the agglomeration of crystals in the reactive crystallization of 5-(difluoromethoxy)-2-mercapto-1
Yongli WANG, Shuyuan MA, Xiaodong Lü, Chuang XIE
《化学科学与工程前沿(英文)》 2012年 第6卷 第4期 页码 423-431 doi: 10.1007/s11705-012-1211-7
关键词:
5-(difluoromethoxy)-2-mercapto-1
基于Lü系统的移动机器人完成特殊情况下全覆盖路径规划的参数值选择策略 Research Article
李彩虹1,刘聪1,宋勇2,梁振英1
《信息与电子工程前沿(英文)》 2023年 第24卷 第2期 页码 231-244 doi: 10.1631/FITEE.2200211
Application of StrucGP in medical immunology: site-specific -glycoproteomic analysis of macrophages
《医学前沿(英文)》 2023年 第17卷 第2期 页码 304-316 doi: 10.1007/s11684-022-0964-8
关键词: macrophage glycoproteome glycopeptides N-glycan structures PD-L1
基于表位定向细胞库筛选高亲和力PD-1突变体诱骗分子 Article
刘昊, 乔春霞, 胡乃静, 王志宏, 王晶, 冯健男, 沈倍奋, 马远方, 罗龙龙
《工程(英文)》 2021年 第7卷 第11期 页码 1557-1565 doi: 10.1016/j.eng.2020.11.011
智能手机成像的晶片上基于逆转录环介导等温扩增(RT-LAMP)技术的全血中HIV-1检测 Article
Gregory L. Damhorst,Carlos Duarte-Guevara,Weili Chen,Tanmay Ghonge,Brian T. Cunningham,Rashid Bashir
《工程(英文)》 2015年 第1卷 第3期 页码 324-335 doi: 10.15302/J-ENG-2015072
病毒载量测量对于人类免疫缺陷病毒 (HIV) 阳性患者长期临床护理来说是一个必不可少的工具。然而,考虑到病毒载量测量所需的仪器体积、成本和操作的复杂性,在医疗基础设施较差的偏远地区 (尤其是在被HIV感染人群比例较高的地区) 普及标准的病毒载量测量仪器是较为困难的。为提高该检测方法的普及性,人们已经开始开发可以进行即时检测的病毒载量检测平台,然而尚没有解决办法能够同时满足低成本、便携、易于操作等多种实际要求。本文通过运用微流体和微型硅晶片平台,对经过最低程度处理的含有HIV的全血样本进行了逆转录环介导等温扩增 (RT-LAMP),并利用智能手机进行了荧光检测。集成实验检测结果表明,一滴约60 nL的反应液滴中仅有的3个病毒依然可以通过RT-LAMP技术被检测到,这相当于每微升全血样品中只有670个病毒。该技术在数字化RT-LAMP方法上具有重要意义,扩展该技术能够实现对HIV阳性患者在临床护理中采集指血进行病毒载量检测。研究结果显示,病毒载量检测过程所需的各个步骤,从血滴的准备到RT-LAMP反应的成像,都可以集成为晶片实验并且可以和移动设备兼容。
关键词: 人类免疫缺陷病毒(HIV) 病毒载量 环介导等温扩增 智能手机 即时检测
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian
《医学前沿(英文)》 2019年 第13卷 第1期 页码 32-44 doi: 10.1007/s11684-018-0678-0
Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.
关键词: immune checkpoint companion diagnosis PD-L1 tumor mutation burden immune score
标题 作者 时间 类型 操作
View-invariant human action recognition via robust locally adaptive multi-view learning
Jia-geng FENG,Jun XIAO
期刊论文
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li
期刊论文
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms
期刊论文
Influence and related mechanism of Retn gene expression on glucose uptake in 3T3-L1 cells
LI Yahui, DONG Shiyuan, YU Chao, JIANG Yu, LI Huaixing, SUN Shuhan
期刊论文
A block zero-padding method based on DCFT for L1 parameter estimations in weak signal and high dynamic
Chao WU,Lu-ping XU,Hua ZHANG,Wen-bo ZHAO
期刊论文
of the agglomeration of crystals in the reactive crystallization of 5-(difluoromethoxy)-2-mercapto-1
Yongli WANG, Shuyuan MA, Xiaodong Lü, Chuang XIE
期刊论文
Application of StrucGP in medical immunology: site-specific -glycoproteomic analysis of macrophages
期刊论文
智能手机成像的晶片上基于逆转录环介导等温扩增(RT-LAMP)技术的全血中HIV-1检测
Gregory L. Damhorst,Carlos Duarte-Guevara,Weili Chen,Tanmay Ghonge,Brian T. Cunningham,Rashid Bashir
期刊论文